Oncogene-induced senescence represents a key tumor suppressive mechanism. Here, we show that Ras oncogene-induced senescence can be mediated by the recently identified haploinsufficient tumor suppressor apoptosis-stimulating protein of p53 (ASPP) 2 through a novel and p53/p19 Arf /p21 waf1/cip1 -independent pathway. ASPP2 suppresses Ras-induced small ubiquitin-like modifier (SUMO)-modified nuclear cyclin D1 and inhibits retinoblastoma protein (Rb) phosphorylation. The lysine residue, K33, of cyclin D1 is a key site for this newly identified regulation. In agreement with the fact that its nuclear localization is required for its oncogenic activity, we show that nuclear cyclin D1 is far more potent than wild-type (WT) cyclin D1 in bypassing Ras-induced senescence. Thus, this study identifies SUMO modification as a positive regulator of nuclear cyclin D1, and reveals a new way by which cell cycle entry and senescence are regulated. Cell Death and Differentiation (2011) 18, 304-314; doi:10.1038/cdd.2010; published online 27 August 2010
Cellular senescence is an irreversible cell cycle arrest and one of the major cellular processes that suppress tumor growth. Cyclin-dependent kinases (CDKs) are among the main regulators of cellular senescence, predominantly achieved through their phosphorylation of the retinoblastoma protein (Rb), preventing it from binding and inhibiting the E2F family of transcription factors that are involved in cell cycle progression. Deregulation of CDK pathways is common in the development of human cancers. Amplification and overexpression of cyclin D1, a regulatory subunit of CDK4/CDK6, has been observed in around 50% of human breast and esophageal cancers. 1, 2 Interestingly, however, elevation of cyclin D1 alone is not sufficient to induce tumor growth in vivo, 3, 4 partly owing to the fact that the cyclin D1/CDK4 or cyclin D1/CDK6 complex needs to locate in the nucleus to phosphorylate Rb during S-phase to promote cell proliferation. 5, 6 Nuclear export, coupled with ubiquitin-dependent destruction of cyclin D1 in the cytoplasm during S-phase, is one of the best known mechanisms of cyclin D1/CDK4 kinase activity control. Hence, nuclear accumulation of cyclin D1 may be a key mechanism by which cyclin D1 exerts its oncogenic effects. In agreement with this, overexpression of mutant cyclin D1 (D1T286A), defective in phosphorylation-mediated nuclear export and subsequent proteolysis, induces cell transformation in vitro and triggers B-cell lymphoma in vivo. 6, 7 Furthermore, transgenic mice overexpressing the same mutant, driven by mouse mammary tumor virus (MMTV) promoter (MMTV-D1T286A), developed mammary adenocarcinoma with a shorter latency relative to mice overexpressing wild-type (WT) cyclin D1 (MMTV-D1). 8 These observations support the notion that the subcellular localization of cyclin D1 is critical in controlling its tumorigenicity. Identifying the molecular mechanisms that regulate the nuclear localization of cyclin D1 is, therefore, vital for our better understanding of tumor development.
SUMOylation is a form of post-translational modification that regulates the cellular localization of modified proteins. Small ubiquitin-like modifiers (SUMOs) are ubiquitin-like polypeptides that become covalently conjugated to cellular proteins in a manner similar to ubiquitylation. 9 In vertebrates, three SUMO isoforms are expressed. SUMO-1 shares 43% identity with SUMO-2 and SUMO-3, whereas the latter two are closely related (sharing 97% identity). The most important differences between the mammalian SUMO paralogues are that the overall cellular concentration of SUMO-2/3 is greater than that of SUMO-1, as is the pool of free protein available for conjugation, 10 and their conjugation pattern: only SUMO-2 and SUMO-3 can form conjugated chains through a single conserved acceptor lysine. Nonetheless, SUMO-1 may terminate chains that are elongated through serial conjugation of SUMO-2/3. 11 The conjugation process involves an enzymatic cascade comprising the E1-activating enzyme activator of SUMO-1, the E2-conjugating enzyme ubiquitin-like protein SUMO-1 conjugating enzyme 9 and E3 ligases including the protein inhibitor of activated STAT family members RAN-binding protein 2 and human polycomb 2.
9,12
Oncogenic stress is one of the best studied cellular senescence-inducing signals and, of the oncogenes identified to date, Ras is the prototype. The Ras oncogene has been shown to predominantly use either p16 ink4a /Rb or the alternate reading frame (Arf)/p21 waf1/cip1 /p53 pathway to mediate cellular senescence. [13] [14] [15] However, it is now becoming clear that Ras oncogene can also induce senescence via p53-independent pathways such as CCAAT/enhancerbinding protein-b, or ones mediated by p63. 16, 17 Apoptosis-stimulating protein of p53 (ASPP) 2 belongs to the evolutionarily conserved ASPP family of proteins that were initially identified through their ability to bind to, and regulate, the apoptotic function of p53 and its family members p63 and p73. 18 Two different ASPP2 transgenic mouse models were generated, expressing either exon 3-or exons 10-17-deleted ASPP2 genes. These two mouse models are referred to here as ASPP2 (D3/D3) and ASPP2 (D10À17/D10À17) , respectively. Importantly, heterozygous mice of ASPP2
and ASPP2
(D10À17/ þ ) are both prone to developing spontaneous tumors, establishing ASPP2 as a new haploinsufficient tumor suppressor. 19, 20 ASPP2 expression is frequently downregulated in human tumors, and reduced ASPP2 expression is tightly associated with patients' poor prognosis. 21, 22 As ASPP2 can bind other cellular proteins including p65 reticuloendotheliosis viral oncogene homolog A, B-cell lymphoma 2, protein phosphatase 1, YES-associated protein, adenomatous polyposis coli-like and amyloid-b precursor protein binding protein 1, [23] [24] [25] [26] [27] [28] it is possible that ASPP2 suppresses tumor growth in ways other than promoting p53-mediated apoptosis. As apoptosis and senescence are two major tumor suppressive pathways, we have investigated whether ASPP2 can exert its tumor suppressive effects by mediating cellular senescence.
Here, we show that Ras oncogene-induced senescence can be mediated by ASPP2 through its ability to prevent Ras from inducing nuclear accumulated cyclin D1. Importantly, ASPP2 mutant cells allowed us to identify SUMO modification as a novel regulation that leads to nuclear localization of cyclin D1. Lysine 33 (K33) of cyclin D1 is predominantly responsible for this newly identified modification. Nuclear localization is vital for the oncogenic properties of cyclin D1 in vitro and in vivo, and this is supported by the observation that nuclear cyclin D1 is able to bypass Ras-induced senescence.
Results
H-RasV12-induced senescence is mediated by ASPP2. Mouse embryonic fibroblasts (MEFs) are a well-established experimental system used to study oncogene-induced senescence. To investigate whether ASPP2 has a role in mediating Ras oncogene-induced senescence, MEFs were generated from ASPP2
embryos, where exon 3 of the murine ASPP2 gene was deleted as previously described, 19 and infected with oncogenic H-RasV12. As expected, the expression of MEFs to investigate whether reintroduction of ASPP2 could mediate H-RasV12-induced senescence. SA-b-Gal activity was detected in around 30% of cells infected (Figure 1d ). In MEFs, Ras-induced cellular senescence is the predominant phenomenon. p53 also predominantly induces senescence rather than apoptosis in Ras-expressing MEFs. In agreement with this, we failed to detect any impact of ASPP2 in inducing apoptosis (data not shown). These results illustrate that ASPP2 is a novel mediator of H-RasV12-induced senescence, which prevents H-RasV12 from transforming MEFs.
ASPP2 mediates Ras-induced senescence by preventing H-RasV12-induced nuclear accumulation of cyclin D1. As Ras oncogene can induce senescence through a p53-dependent pathway and ASPP2 was originally identified as a p53 activator, we checked whether ASPP2 could affect H-RasV12-induced expression of p19 To examine whether ASPP2 mediates Ras oncogeneinduced senescence through the Rb pathway, we compared the phosphorylation status of Rb in ASPP2 ( þ / þ ) and ASPP2 (D3/D3) MEFs. Similar amounts of phosphorylated Rb were detected in both ASPP2
( þ / þ ) and ASPP2 (D3/D3) MEFs. Interestingly, Ras oncogene only induced a clear reduction in Rb phosphorylation in ASPP2 ( þ / þ ) MEFs, but caused a marked three-fourfold increase in the amount of phosphorylated Rb in H-RasV12-expressing ASPP2 (D3/D3) MEFs (Figure 2b ). These results suggest that ASPP2 is required for Ras oncogene to inhibit Rb phosphorylation, and ASPP2 may use this property to mediate Ras oncogene-induced senescence.
To understand how H-RasV12 affects Rb phosphorylation in the absence of functional ASPP2, we investigated the expression levels of CDKs and their inhibitors in ASPP2
(D3/D3) MEFs, with or without H-RasV12 infection. The expression levels of CDK4, p16 ink4a , p27kip1, cyclin E, cyclin A and CDK2 were not affected by ASPP2 status (Figure 2c ). Interestingly, however, ASPP2 status did affect the expression pattern of cyclin D1. Although cyclin D1 protein levels were increased in both H-RasV12-expressing ASPP2 ( þ / þ ) and ASPP2 (D3/D3) MEFs, increased cyclin D1 was often associated with the expression of higher molecular weight (MW) protein bands in H-RasV12-expressing ASPP2 (D3/D3) MEFs, detected by at least two different ASPP2 regulates nuclear localization of cyclin D1 XD Wang et al anti-cyclin D1 antibodies ( Figure 2c and data not shown). This suggests that ASPP2 may mediate the post-translational modification of cyclin D1, induced by Ras oncogene. It is important to note that we failed to detect similar changes in p53 ( þ / þ ) and p53 (À/À) MEFs, irrespective of Ras expression ( Figure 2d ). Hence only ASPP2, but not p53, may influence cyclin D1 expression in response to Ras oncogene. As cyclin D1 is a regulatory subunit of CDKs that phosphorylate Rb, this observation suggests that modified cyclin D1 may be responsible for the observed increase in Rb phosphorylation.
It has also been reported that only nuclear cyclin D1 confers tumor growth. 29 Remarkably, ASPP2 (D3/D3) MEFs had a prominent, fourfold higher number of nuclear cyclin D1-expressing cells in response to H-RasV12 induction compared with ASPP2
( þ / þ ) MEFs (Figure 2e ). In contrast, no difference was observed in the nuclear localization of Figure 1) . Furthermore, H-RasV12-induced nuclear accumulation of cyclin D1 was specifically prevented by ASPP2, but not p53, as similar numbers of nuclear cyclin D1 were detected in Ras-expressing p53 ( þ / þ ) and p53
MEFs ( Figure 2e , middle panel). This confirms that the pathway regulated by Ras and ASPP2 is p53-independent. Together, the results show that ASPP2 mediates H-RasV12-induced senescence by preventing H-RasV12 from inducing nuclear cyclin D1, Rb phosphorylation and cell cycle entry.
H-RasV12 induces SUMOylation of cyclin D1. Owing to the large change in gel mobility, we hypothesized that cyclin D1 modification was likely caused by molecules that can form large chains, such as ubiquitin or SUMO. As cyclin D1's ubiquitination may be influenced by Ras, 30 we tested cells. The high MW cyclin D1 observed in Figure 2c was highly insoluble and only detected when 8 M urea buffer was used to lyse the cells. Thus, 8 M urea cell lysates were first diluted 10-fold in NP-40 buffer to refold the solubilised and denatured high MW cyclin D1, to allow an anti-cyclin D1 antibody to specifically immunoprecipitate cyclin D1. The presence of ubiquitinated cyclin D1 was analyzed using an anti-ubiquitin antibody. Interestingly, H-RasV12 expression did not significantly alter the expression pattern of ubiquitinated proteins in ASPP2 (D3/D3) cells (Figure 3a,  lanes 1-4) . Furthermore, the ubiquitinated cyclin D1 expression pattern was similar between vector or H-RasV12-expressing ASPP2 (D3/D3) cells (Figure 3a , lanes 5 and 6). Treatment with the proteasome inhibitor MG132 also had a minimal impact on the expression pattern of ubiquitinated cyclin D1 (Figure 3a, lanes 8 and 9) . Importantly, ubiquitinated cyclin D1 had a completely different mobility pattern than that observed in Figure 2c , suggesting that the high mobility cyclin D1 bands detected in H-RasV12-expressing ASPP2 (D3/D3) cells were not caused by altered ubiquitination activity. SUMO modification, particularly by SUMO-2 and SUMO-3, often alters a protein's cellular localization. Knowing that modified cyclin D1 is tightly associated with the accumulation of nuclear cyclin D1, we tested whether cyclin D1 could be SUMO-modified and whether this modification was altered in H-RasV12-expressing ASPP2 (D3/D3) cells. Interestingly, we detected an enrichment of SUMO-2/SUMO-3-modified protein in H-RasV12-expressing ASPP2 (D3/D3) cells, in comparison with ASPP2
(D3/D3) cells expressing vector only (Figure 3b, compare lanes 1 and 2) . We also detected a distinct expression pattern of high MW bands in cyclin D1 immunoprecipitates derived from H-RasV12-expressing ASPP2 (D3/D3) MEFs compared with those expressing vector only (Figure 3b, lanes 3 and 4) . In particular, we detected an enrichment of SUMO-modified cyclin D1 with MWs raging from 35 to 50 kDa (e.g., labelled band 2 and 3). These results suggest that cyclin D1 may be SUMO-modified, and that H-RasV12 enhances this modification in ASPP2 (D3/D3) MEFs. (D3/D3) MEFs, with or without H-RasV12 expression, were transfected with 1 mg of cyclin D1-expressing plasmid, with or without 1 mg of plasmid expressing 6His-tagged SUMO-1 or 6His-tagged SUMO-2 and 6His-tagged SUMO-3. 6His-tagged SUMOs were trapped on a nickel column, and SUMOylated products separated and analyzed with anti-cyclin D1 antibody to detect SUMO-modified cyclin D1 as indicated
To provide further evidence that cyclin D1 can be SUMOmodified, we cotransfected His-tagged SUMO-expressing plasmids together with cyclin D1 into ASPP2 (D3/D3) MEFs, with or without H-RasV12. Expressed His-tagged SUMO was pulled down by nickel beads and the presence of cyclin D1 was detected by an anti-cyclin D1 antibody. Under the conditions used, the nickel beads pulled down the cotransfected cyclin D1 non-specifically (Figure 3c, lanes 1 and 2) . However, when cotransfected with SUMO-1, they pulled down more cyclin D1 with a high MW, similar to that seen in Figure 3b . Furthermore, the presence of H-RasV12 enriched the amount of SUMO-modified cyclin D1 (Figure 3c, lanes 3  and 4, in particular band 3 in lane 4) . The amount of high MW cyclin D1 was further increased when SUMO-1-3 were coexpressed with cyclin D1 (Figure 3c , lanes 5 and 6, in particular bands 2 and 3 in lane 6). The pattern of high MW cyclin D1 resembled that detected by probing immunoprecipitated endogenous cyclin D1 with anti-SUMO antibody. These results illustrate that cyclin D1 is SUMO-modified, and that this modification is induced by H-RasV12 in ASPP2 (D3/D3) MEFs.
SUMO modification leads to nuclear accumulation of cyclin D1. SUMO modification is often associated with the specific cellular localization of modified proteins. Thus, we checked the localization of exogenously expressed cyclin D1 in a human osteosarcoma cell line (U2OS), which expresses endogenous Ras and ASPP2, in the presence of SUMO-1-, SUMO-2-and SUMO-3-expressing plasmids. Nuclear cyclin D1 was detected in more than 60% of U2OS cells coexpressing cyclin D1 and SUMO-2 and 3 (but not SUMO-1; Figure 4a ). To confirm the role of SUMOylation in the nuclear localization of cyclin D1, we infected H-RasV12-expressing ASPP2 (D3/D3) MEFs with adenovirus-expressing sentrin-specific protease 2 (SENP2), a protease that specifically removes SUMO modifications. We observed that nuclear cyclin D1 disappeared from cells infected by SENP2-expressing adenovirus, but not from cells infected by control virus, (Figure 4b ), suggesting that SUMO modification is required for the accumulation of nuclear cyclin D1.
SUMO modification on K33 is critical for the nuclear localization of cyclin D1. Sequence analysis performed with the SUMOsp web server 31 revealed the existence of four putative SUMOylation sites on cyclin D1: a canonical one at K33, and three type II sites at K72, K95 and K96 (Figure 5a ). To identify the lysine residue important for cyclin D1 modification and nuclear localization, residues K33, K72, K95 and K96 were individually mutated to alanine to generate non-modifiable cyclin D1 mutants K33A, K72A, K95A and K96A, respectively. The cellular localizations of exogenously expressed cyclin D1 and its mutants in the presence of SUMO-2-and SUMO-3-expressing plasmids ( Figure 5b) were then examined. Interestingly, nuclear cyclin D1 was detected in 60-70% of the cells coexpressing cyclin D1, cyclin D1-K72A, cyclin D1-K95A and cyclin D1-K96A with SUMO-2 and SUMO-3, but only in 15% of the cells coexpressing cyclin D1-K33A and SUMO-2 and SUMO-3. These results demonstrate that SUMO is likely to modify cyclin D1 on K33, and that K33 is critical for cyclin D1's nuclear localization.
Nuclear cyclin D1 is more potent than WT cyclin D1 in rescuing Ras-induced senescence. Cyclin D1 is phosphorylated by glycogen synthase kinase 3b (GSK-3b) on a conserved C-terminal threonine, T-286, during the G1/S 5 By mutating T-286 to A-286, the resulting mutant cyclin D1 T286A is refractory to GSK-3b-dependent phosphorylation and CRM export, so is constitutively nuclear. Importantly, transgenic mouse model studies have shown that the nuclear cyclin D1 T286A mutant, but not WT cyclin D1, promotes cell transformation in vitro and tumor growth in nude mice when overexpressed. 3, 4, 6, 32 We hypothesized that ASPP2 mediates H-RasV12-induced senescence by preventing the nuclear accumulation of cyclin D1. Cyclin D1 is, therefore, a downstream effecter of ASPP2, and nuclear cyclin D1 should be able to bypass H-RasV12-induced senescence in ASPP2
(
MEFs were infected with oncogenic H-RasV12 alone, or in combination with cyclin D1 or cyclin D1 T286A. Protein expression levels and cellular localization of WT and cyclin D1 T286A were then examined via immunoblotting and immunofluuresence staining (Figure 6a ( þ / þ ) MEFs underwent senescence when infected with retroviruses expressing either cyclin D1 or cyclin D1 T286A. Under the same conditions, however, around 90% of the cells infected with H-RasV12 alone stained positive for SA-b-Gal. When cells were co-infected with H-RasV12 and WT cyclin D1, the number of SA-b-Gal-positive cells reduced to around 65%. Perhaps most importantly, when H-RasV12 was co-infected with nuclear cyclin D1 T286A, only 25% of the cells stained positive for SA-b-Gal. Interestingly, the SA-b-Gal staining pattern was almost a mirror image of that of BrdU-labelled cells (Figure 6d and f) . These results demonstrate that nuclear cyclin D1 is more potent than the WT in bypassing Ras oncogene-induced cellular senescence.
Discussion
By investigating the mechanisms that ASPP2 uses to mediate Ras oncogene-induced senescence, we identified SUMOylation as a novel mechanism that regulates the nuclear localization of cyclin D1. We also showed that nuclear cyclin D1 is more effective than WT cyclin D1 in bypassing Rasinduced cellular senescence.
Existing studies have demonstrated that cyclin D1 is exported from the nucleus to the cytoplasm. At G1 phase, cyclin D1 complexes with CDK4 and translocates to the nucleus, to phosphorylate Rb following CDK-activating kinase activation. GSK-3b kinase then enters the nucleus during G1/S transition and phosphorylates cyclin D1 at T-286, 5, 34 triggering CRM1-mediated nuclear export of cyclin D1. 35 Once T286-phosphorylated cyclin D1 is exported to the cytoplasm, it is ubiquitinated and degraded by the proteosome. 32 In contrast, however, very little is known about the mechanism that regulates cyclin D1's nuclear entry. In our attempts to understand how ASPP2 mediates Ras oncogeneinduced senescence, we have identified one mechanism by which cyclin D1's nuclear accumulation is regulated. Cyclin D1 is SUMO-modified by SUMO-2/3 (but not SUMO-1), and ASPP2 inhibits Ras oncogene-induced SUMO modification of endogenous cyclin D1 in vivo. Interestingly, SUMO-modified cyclin D1 was nuclear and insoluble, as SUMO-modified cyclin D1 could only be detected when cells were lysed with 8 M urea. This may explain why SUMO-modified cyclin D1 has not previously been identified by conventional immunoprecipitation or kinase assays. The insoluble nature of SUMOmodified cyclin D1 is in agreement with its nuclear localization. To detect SUMO-modified endogenous cyclin D1 in Rasexpressing ASPP2 mutant cells, SUMOylated cyclin D1 was denatured with 8 M urea and the protein was refolded in diluted buffer for immunoprecipitation. This refolding process is likely to only work with a proportion of the population of SUMO-modified cyclin D1, and may be a reason why the mobility shifts of cyclin D1 observed in Figures 2c and 3b are similar but not identical. Furthermore, we do not yet know the molecular mechanisms by which ASPP2 prevents Ras oncogene from inducing SUMO cyclin D1's SUMO modification.
Previous studies have shown that SUMO-modified proteins tend to locate in the nucleus. 36 In some proteins, nuclear accumulation by SUMO modification is achieved by interference with nuclear export signal (NES) functions. By modifying a site in close proximity to a NES, SUMO modification may inhibit nuclear export by masking the NES signal. Although the identified K33 of cyclin D1 is not in close proximity to any known cyclin D1 NES, the two lysine residues (K95 and K96) in close proximity to the first NES of cyclin D1 failed to influence its nuclear localization when coexpressed with SUMO-2 and SUMO-3. How SUMO modification at K33 can influence the nuclear localization of cyclin D1, therefore, remains unknown. Future studies are needed to test whether SUMO modification on K33 can mask an NES or expose a nuclear localization signal (if one exists) of cyclin D1, or whether it causes nuclear retention by facilitating cyclin D1's association with nuclear factors or structures. Regardless of how K33 SUMO modification causes cyclin D1's nuclear localization, we show here that SUMOylated nuclear cyclin D1 is active in phosphorylating Rb, as the amount of phosphorylated Rb detected in H-RasV12-expressing ASPP2 mutant MEFs is much higher than that in ASPP2 WT MEFs. This also agrees with the finding that nuclear cyclin D1 is far more potent than the WT in bypassing Ras oncogene-induced senescence.
Mutation of Ras oncogene and overexpression of cyclin D1 occur frequently in human cancers. In colon and breast cancers, for example, mutation of Ras and overexpression of cyclin D1 can be as high as 50%. 1, 33, 37 It is also interesting to note that downregulation of ASPP2 in human breast cancers was also observed in over 20% of mutant p53-expressing tumors. 18 Furthermore, a large percentage of human tumors overexpress nuclear cyclin D1, and nuclear localization is required for the oncogenic properties of cyclin D1. Thus, it will be interesting to identify whether nuclear cyclin D1 expression is associated with Ras mutation and/or a reduced expression of ASPP2. Importantly, inhibiting cyclin D1's SUMO modification may be beneficial in the treatment of patients expressing high levels of nuclear cyclin D1.
Materials and Methods
Cell culture and genotyping. MEFs were prepared from day 13.5 embryos from XTV-ASPP2 ( þ /D3) intercrosses. Genotyping was performed by PCR using primers a (5 0 -CCTCTCACAAAAGGAAATAACCTG-3 0 ), b (5 0 -AGGAAAACCACCA CCTTCAC-3 0 ) and c (5 0 -TACCCGCTTCCATTGCTCAG-3 0 ). Primers a and b amplify a 900 base pair -(bp) fragment from the WT allele, and primers b and c amplify a 1100-bp fragment from the knockout allele. p53 MEFs were prepared from day 13.5 embryos from p53 ( þ /À) intercrosses. All MEFs and U2OS cells were cultured in DMEM supplemented with 10% fetal bovine serum and penicillinstreptomycin (Gibco-BRL, Invitrogen Ltd, Paisley, UK).
Plasmids. pBabe-Puro Ha-RasV12 and pBabe-Bleo Ha-RasV12 were obtained from Julian Downward (Cancer Research UK, London, UK). pBabe-Puro cyclin D1 and pBabe-Puro cyclin D1-T286A were obtained from Alan Diehl (University of Pennsylvania, Philadelphia, PA, USA). pBabe-Puro cyclin D1-K33A, K72A, K95A and K96A were obtained by site-directed mutagenesis. The following primers were used: K33A (GCGGGCCATGCTGGCGGCGGAGGAGACCTGC); K72A (GGTC TGCGAGGAACAGGCGTGCGAGGAGGAGG); K95A (CGCTGGAGCCCGTGGC AAAGAGCCGCCTGCAGC); K96A (CGCTGGAGCCCGTGAAAGCGAGCCGCCT GCAGC). The retroviral vector for ASPP2 was generated by cloning ASPP2 cDNA fragments into pLPCX-Puro using XhoI and NotI restriction enzymes. 6His-tagged SUMO-1, SUMO-2 and SUMO-3 were cloned in pcDNA3 using BamHI and EcoRI restriction enzymes.
Western blot (WB) analysis. WB analysis was performed with lysates prepared 6-8 days after transduction of Ras from subconfluent cells, with urea buffer (8 M urea, 1 M thiourea, 0.5% 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate (CHAPS), 50 mM dithiothreitol (DTT) and 24 mM Spermine) or NP40 lysis buffer (1%NP40, 0.5% sodium deoxycholate in phosphate-buffered saline (PBS)) as described. 38 Primary antibodies were from: Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA (p21 waf1/cip1 (F-5), cyclin E, cyclin A, CDK2), Abcam Inc., Cambridge, MA, USA (tubulin, cyclin D1(DCS-6), p16 ink4a , p19
Arf ), Novocastra/Leica Microsystems GmbH, Wetzlar, Germany (p53(CM-5)), BD Biosciences, Franklin Lakes, NJ USA (Ras, Rb), Upstate Millipore Corporate Headquarters, Billerica, MA, USA (Ras clone 10), Cell Signaling Technology, Inc., Danvers, MA, USA (cyclin D1, CDK4, ubiquitin) and Invitrogen (SUMO-2/3). Anti-ASPP2 antibodies were generated in rabbits and the serum was named S32. To detect p27kip1, we used the mouse monoclonal SX53.G8. Signals were detected using the ECL detection system (GE Healthcare, Pollards Wood, Chalfont, Buckinghamshire, UK).
Indirect immunofluorescence. Cells were fixed in 4% PBSparaformaldeyde for 15 min, incubated in 0.2% Triton-X-100 for 5 min, then in 0.2% Fish Skin Gelatine in PBS for 10 min and stained for 30 min with an anti-cyclin D1 antibody (Abcam), anti-His (Santa Cruz), anti-BrdU fluorescein isothiocyanate (BD bioscience) or anti-p21 waf1/cip1 (SX118). Antibodies were used at 1 : 50 dilution in 0.2% Fish Skin Gelatine-PBS. Staining with the secondary antibody was performed as previously described, 39 followed by visualization under a fluorescence microscope. All the procedures were performed at 201C.
Analysis of senescence. Analysis of senescence in cell culture was performed using a Senescence b-galactosidase staining kit (Cell Signaling) as described previously. 38 To quantify SA-b-gal positives, at least 200 cells were counted in random fields in each of the duplicated wells.
Transformation assays. A total of 10 5 ASPP2 (D3/D3) and ASPP2
MEFs were infected with pBABE-Puro H-RasV12 or empty vector retroviruses. Cells were selected with puromycin for 4 days, and plates were then fixed and stained with Giemsa 4 weeks later. For anchorage-independent growth, 5 Â 10 4 cells transduced with pBABE-Puro H-RasV12 were resuspended in medium containing 0.3% low-melting-point agarose and plated onto solidified bottom layer medium containing 0.5% agarose. Colonies were photographed and counted after 3-4 weeks.
Immunoprecipitations. Cells were lysed in urea buffer (8 M urea, 1 M thiourea, 0.5% CHAPS, 50 mM DTT and 24 mM Spermine), after which extracts were diluted 10-fold in NP40 lysis buffer (1%NP40, 0.5% sodium deoxycholate in PBS) and precleared with 60 ml of protein G beads (50% slurry) for 60 min at 41C. For each immunoprecipitation, 25 ml anti-cyclin D1 mAb (Abcam) or IgG was used, 25 ml of 50% slurry of protein G beads were added and then samples were rotated at 41C overnight. Beads were washed five times with 1 ml of 10-fold diluted urea buffer and 20 ml of 2 Â SDS loading buffer was added. Immunoprecipitations were analyzed by WB as indicated.
Purification of 6His-tagged SUMO-cyclin D1 conjugates. At 36 h post-transfection, cells were washed twice with PBS and scraped in 1 ml of PBS. In all, 20% of the cell suspension was used for direct WB analysis. The remainder was lysed in 6 ml of 6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 Eluates were mixed at a 1 : 1 ratio with 2 Â Laemmli-buffer and analyzed by WB.
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